Sahajanand Medical Technologies is a Class III and Class C/D medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. The company was founded by Dhirajlal Kotadia in 2001. The company was the first company in the world to receive a CE certification for a DES with a biodegradable polymer-based paclitaxel-eluting stent (Infinnium). Over the years, the company has introduced several innovative products, driven by its focus on research and development and precision manufacturing capabilities enabling it to deliver quality products backed by clinical data. The company is a R&D-driven company engaged in the development of Class III and Class C/D medical devices, with an emphasis on Vascular Intervention (VI) and Structural Heart (SH). The company’s portfolio of (i) VI products includes coronary intervention products such as coronary stents and coronary balloons, (ii) SH products include TAVI and Occluders, and (iii) Others including its own brand of renal stents, peripheral DCBs and other trading products.

The company markets its products in various countries (including India) through a mix of direct, hybrid, and distributor-led models, adapting to local regulatory and market conditions. In India, through its hybrid model, it caters to large hospitals, including Narayana Hrudayalaya Limited. In Europe, it has direct operations in major markets such as Germany, Spain, France and UK, successfully navigating complex regulatory and procurement environments. In certain other regions, such as Italy, it uses distributor-led models for efficient market entry and scaling. Its international revenue share has grown steadily over the past three years, reflecting increasing global acceptance and diversification of its business. 

Business area of the company

Sahajanand Medical Technologies is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention. The company has strong research and development capabilities. It also has diversified and integrated manufacturing facilities.

Products of the company

VI products: VI refers to minimally invasive procedures used to diagnose or treat diseases of blood vessels.

• Drug eluting stents
• Drug-coated PTCA Balloon / Coronary Drug-coated Balloon (DCB)
• Percutaneous transluminal coronary angioplasty (PTCA) balloon dilatation catheter

SH products, SH refers to minimally invasive procedures used to treat defects or abnormalities in the heart’s structure.

• TAVI (Transcatheter Aortic Valve Implantation)
• Occluders

Other product

• Renofit 
• Percutaneous Transluminal Angioplasty Drug Coated Balloon (PTA DCB)

Awards, accreditations, and recognition

• 2016: “National Award for Technology Innovation in Petrochemicals and Downstream Plastics Processing Industry” in the category of polymers in public health care by Ministry of Chemicals and Fertilizers, Government of India.
• 2020: Awarded “SBI General Insurance SME Award’ in the pharmaceuticals, drugs and medical products category” by Times Network.
• 2022: Awarded “National Award 2022 for successful development and commercialization of indigenous technology” by the Technology Development Board (TDB), Government of India.
• 2022: Awarded “CPHI India Pharma 2022 Award in Excellence in R&D- Development of new product/technology” by Informamarkets.
• 2023: Awarded 13th MT India Healthcare Awards for “Most Promising Medical Devices Company in Make in India Initiative”.
• 2025: Awarded “Excellence in Clinical Evidence” for 35,000 plus patient clinical program by CSI NIC.
• 2025: Awarded 15th MT India Healthcare Awards for “Leading Company of the Year in Medical Devices”.
• 2025: Awarded Voice of Healthcare Cardiac Excellence Awards 2025 for “Excellence in Cardiovascular Therapeutics”.
• 2025: Awarded National Healthcare Award for Innovative Medical Device of the Year-HYDRA.
• 2025: 11th CII Industrial Intellectual Property Awards 2025: Top 50 IP Driven Organisation.
• 2025: Awarded as the winner in the category of “Excellence in Export Promotion” at the 12th edition of India Pharma Awards 2025 by Informa Markets Pvt. Ltd.

History and milestones

• 2016: Samara Capital Markets Holding Limited invested around Rs 400 million by subscribing to 9,406,419 Equity Shares of the company. Additionally, Samara Capital Markets Holding also purchased 9,406,419 Equity Shares of the company from existing shareholders for a consideration around Rs 400 million.
• 2017: Samara Capital Markets Holding Limited invested Rs 700 million by subscribing to 13,717,421 Equity Shares of the Company.
• 2017: Enrolment of 1,435 patients completed for TALENT trial on the safety and efficacy of a sirolimus eluting coronary stent.
• 2018 NHPEA Sparkle Holding B.V. invested Rs 1,600 million by subscribing to 16,396,803 Equity Shares of the Company.
• 2019: TALENT trial study for Supraflex presented by Professor Patrick Serruys and published in The Lancet.
• 2019: Received EC Certificate for full quality assurance system granted to Supraflex Cruz.
• 2019: Acquired Imex Salud S.L. to establish direct operations in Spain, for a sum of 2.55 million euro.
• 2019: Acquired 75% of the quotas of SMT Brazil (erstwhile Zarek Distribuidora De Produtos Hospitalares Eireli) to establish hybrid operations in Brazil, for a sum of Rs 18.82 million.
• 2020: Acquired VCL (as an erstwhile subsidiary of the Company) for a consideration of Rs 687.29 million.
• 2020: Acquired Vascular Innovations, a wholly owned subsidiary of SMT Ireland, for a sum of 443.00 million Thai Baht.
• 2022: Publication of the safety and performance study of “Hydra TAVI” in JACC: Cardiovascular Interventions, demonstrating its efficacy in the treatment of symptomatic severe aortic stenosis.
• 2024: Launch of Hydra TAVI in Russia, Malaysia and Hungary.
• 2024: Completion of patient enrolment for TUXEDO-2, a clinical trial to evaluate the efficacy of drug eluting stent “Supraflex Cruz” in diabetic patients with multi vessel coronary artery disease.
• 2024: TGA Australia’s approval for drug eluting stent “Supraflex Cruz”.
• 2024: Publication of S-FLEX UK-II Registry study on “Supraflex Cruz” demonstrating its clinical safety and performance in BMJ Open.
• 2024: Publication of the Compare 60/80 HBR trial study in Circulation: Cardiovascular Interventions demonstrating the efficacy of “Supraflex Cruz” in high bleeding risk patients.
• 2025: SMT Ireland, its wholly owned Subsidiary, purchased shares of the common stock of SNP Medical Corporation.
• 2025: Publication of 3 year follow up outcomes of the FIRE Trial of “Supraflex Cruz” in Jama Cardiology, demonstrating sustained clinical benefits of Supraflex Cruz in older patients (>75 years) with myocardial infarction and multivessel disease.
• 2025: Publication of 30 day and 6 months follow up outcomes of the GENESIS -II study of Hydra Transcatheter heart valve device in Asia Intervention and Euro PCR 2025, respectively, demonstrating its safety and performance in treating severe aortic stenosis in high-risk patients.
• 2025: Presentation of the results of TUXEDO-2, multivessel TALENT trial and Cruz Senior Study, along with results of SFlex Netherlands Registry demonstrating the non-inferiority, proven safety, efficacy, and consistent performance of the Supraflex Cruz across a broad spectrum of complex patient populations, at Transcatheter Cardiovascular Therapeutics 2025.